Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

9
results for

"Ju Hyun Kim"

Article category

Keywords

Publication year

"Ju Hyun Kim"

Original Articles

Viral hepatitis

Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial
Do Seon Song, Won Kim, Sang Hoon Ahn, Hyung Joon Yim, Jae Young Jang, Young Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Young Kul Jung, Joo Hyun Sohn, Jin-Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Jin Mo Yang, Kyun-Hwan Kim, Kwang-Hyub Han, Soon Ho Um
Clin Mol Hepatol 2021;27(2):346-359.
Published online January 25, 2021
DOI: https://doi.org/10.3350/cmh.2020.0307
Background/Aims
Besifovir dipivoxil maleate (BSV), an acyclic nucleotide phosphonate, shows potent antiviral activity against hepatitis B virus. Our previous 48-week trial revealed that BSV has comparable antiviral efficacy to tenofovir disoproxil fumarate (TDF) and better safety profiles in terms of improved renal and bone safety. This extension study evaluated the prolonged efficacy and safety of BSV in treatment-naive chronic hepatitis B patients.
Methods
Patients continued to participate in an open-label BSV study after an initial 48-week double-blind comparison of BSV and TDF treatment. The antiviral efficacy and drug safety was evaluated up to 192 weeks in two groups: patients continuing BSV treatment (BSV-BSV) and patients switching from TDF to BSV after 48 weeks (TDF-BSV).
Results
Among 197 patients receiving randomized treatments, 170 (86%) entered the open-label phase and 152 (77%) entered the 192-week extension study. Virological response rates over 192 weeks were 92.50% and 93.06% in the BSV-BSV and TDF-BSV groups, respectively (P=0.90). Hepatitis B envelop antigen seroconversion and alanine aminotransferase normalization rates were similar between the groups (P=0.75 and P=0.36, respectively). There were no drug-resistant mutations to BSV. Bone mineral density and renal function were well preserved in the BSV-BSV group, whereas these initially worsened then recovered after switching therapy in the TDF-BSV group.
Conclusions
BSV maintained potent antiviral efficacy after 192 weeks and showed no evidence of drug resistance. BSV was safe, well tolerated, and effective in patients who switched from TDF to BSV. Trial Registration Number: NCT01937806 (date: 10 Sep 2013).

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
    Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
    Clinical and Molecular Hepatology.2026; 32(1): e55.     CrossRef
  • Prodrug strategies in developing antiviral nucleoside analogs
    R. Rama Suresh, Tuniyazi Abuduani, Mahesh Kasthuri, Zhe Chen, Zahira Tber, Mohammed Loubidi, HongWang Zhang, Longhu Zhou, Shaoman Zhou, Chenwei Li, Amita Kumari, Sijia Tao, John M. Wiseman, Selwyn J. Hurwitz, Franck Amblard, Raymond F. Schinazi
    RSC Medicinal Chemistry.2026; 17(1): 105.     CrossRef
  • Comparison of hepatocellular carcinoma incidence after long-term treatment with besifovir vs. tenofovir AF
    Hyuk Kim, Jae-Young Kim, Yoon E. Shin, Hye-Jin Yoo, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial
    Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Wo
    Clinical and Molecular Hepatology.2025; 31(3): 810.     CrossRef
  • Besifovir dipivoxil maleate versus other antivirals in reducing hepatocellular carcinoma in chronic hepatitis B
    Jae Seung Lee, Sung Won Lee, Hae Lim Lee, Jeong-Ju Yoo, Yeon Seok Seo, Su Jong Yu, Hyung Joon Yim, Young Kul Jung, Jisu Moon, Hye Won Lee, Mi Na Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Sang Gyune Kim, Seung Up Kim
    Scientific Reports.2025;[Epub]     CrossRef
  • Comparative Renal Safety of Besifovir Dipivoxil Maleate and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients: Insights From a Nationwide Cohort Study
    Hyun Bin Choi, Jae Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
    European Journal of Clinical Investigation.2023;[Epub]     CrossRef
  • Comparison of decline in renal function between patients with chronic hepatitis B with or without antiviral therapy
    Jae Seung Lee, Chan‐Young Jung, Jung Il Lee, Sang Hoon Ahn, Beom Seok Kim, Seung Up Kim
    Alimentary Pharmacology & Therapeutics.2023; 58(1): 99.     CrossRef
  • Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis
    Hui Liu, Cheng-Long Han, Bao-Wen Tian, Zi-Niu Ding, Ya-Fei Yang, Yun-Long Ma, Chun-Cheng Yang, Guang-Xiao Meng, Jun-Shuai Xue, Dong-Xu Wang, Zhao-Ru Dong, Zhi-Qiang Chen, Jian-Guo Hong, Tao Li
    Expert Review of Gastroenterology & Hepatology.2023; 17(6): 623.     CrossRef
  • Prediction model of hepatitis B virus-related hepatocellular carcinoma in patients receiving antiviral therapy
    Beom Kyung Kim, Sang Hoon Ahn
    Journal of the Formosan Medical Association.2023; 122(12): 1238.     CrossRef
  • Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient
    Jong Chul Kim, Hye Young Lee, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Juhee Won, Soree Park, Na Yeon Kim, Jae Jin Shin, Sang Gyune Kim, Young Seok Kim, Jeong-Ju Yoo, Kyun-Hwan Kim
    Biomedicines.2022; 10(2): 282.     CrossRef
  • KASL clinical practice guidelines for management of chronic hepatitis B

    Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
  • Susceptibility of Drug Resistant Hepatitis B Virus Mutants to Besifovir
    Juhee Won, Ah Ram Lee, Mehrangiz Dezhbord, Da Rae Lee, Seong Ho Kim, Jong Chul Kim, Soree Park, Nayeon Kim, Byengjune Jae, Kyun-Hwan Kim
    Biomedicines.2022; 10(7): 1637.     CrossRef
  • Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B
    Jeong Eun Song, Jun Yong Park
    Expert Opinion on Pharmacotherapy.2021; 22(18): 2427.     CrossRef
  • Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
    Sung Won Lee, Jonggi Choi, Seung Up Kim, Young-Suk Lim
    Clinical and Molecular Hepatology.2021; 27(3): 402.     CrossRef
  • 10,367 View
  • 268 Download
  • 17 Web of Science
  • Crossref

Viral hepatitis

The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
In Ku Yo, Oh Sang Kwon, Jin Woong Park, Jong Joon Lee, Jung Hyun Lee, In Sik Won, Sun Young Na, Pil Kyu Jang, Pyung Hwa Park, Duck Joo Choi, Yun Soo Kim, Ju Hyun Kim
Clin Mol Hepatol 2015;21(1):32-40.
Published online March 25, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.1.32
Background/Aims

Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors that improve LS.

Methods

Between April 2007 and December 2012, 151 patients with CHB who underwent two TE procedures with an interval of about 2 years were enrolled. Ninety-six of the 151 patients were treated with nucleos(t)ide analogues [the antiviral therapy (+) group], while the remaining 55 patients were not [the antiviral therapy (-) group]. The two groups of patients were stratified according to whether they exhibited an improvement or a deterioration in LS during the study period (defined as an LS change of ≤0 or >0 kPa, respectively, over a 1-year period), and their data were compared.

Results

No differences were observed between the antiviral therapy (+) and (-) groups with respect to either their clinical characteristics or their initial LS. The observed LS improvement was significantly greater in the antiviral therapy (+) group than in the antiviral therapy (-) group (-3.0 vs. 0.98 kPa, P=0.011). In the antiviral therapy (+) group, the initial LS was higher in the LS improvement group (n=63) than in the LS deterioration group (n=33; 7.9 vs. 4.8 kPa, P<0.001). However, there were no differences in any other clinical characteristic. In the antiviral therapy (-) group, the initial LS was also higher in the LS improvement group (n=29) than in the LS deterioration group (n=26; 8.3 vs. 6.5 kPa, P=0.021), with no differences in any other clinical characteristic.

Conclusions

A higher initial LS was the only factor associated with LS improvement in patients with CHB in this study.

Citations

Citations to this article as recorded by  Crossref logo
  • Predictive validation of qualitative fibrosis staging in patients with chronic hepatitis B on antiviral therapy
    Hye Won Lee, Kiyong Na, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Ji Hae Nahm, Jung Il Lee, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Young Nyun Park
    Scientific Reports.2019;[Epub]     CrossRef
  • The Influence of Histologic Inflammation on the Improvement of Liver Stiffness Values Over 1 and 3 Years
    Jeong-Ju Yoo, Yeon Seok Seo, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Sang Jun Suh, Hyung Joon Yim, Ki Tae Suk, Dong Joon Kim, Kwang-Hyub Han, Seung Up Kim, Bora Lee, Sang Gyune Kim
    Journal of Clinical Medicine.2019; 8(12): 2065.     CrossRef
  • Diagnostic Performance of Serum Asialo-α1-acid Glycoprotein for Advanced Liver Fibrosis or Cirrhosis in Patients with Chronic Hepatitis B or Nonalcoholic Fatty Liver Disease
    Seung Up Kim, Mi Young Jeon, Tae Seop Lim
    The Korean Journal of Gastroenterology.2019; 74(6): 341.     CrossRef
  • Reversal of liver cirrhosis: current evidence and expectations
    Young Kul Jung, Hyung Joon Yim
    The Korean Journal of Internal Medicine.2017; 32(2): 213.     CrossRef
  • Improvement of Liver Fibrosis after Long-Term Antiviral Therapy Assessed by Fibroscan in Chronic Hepatitis B Patients With Advanced Fibrosis
    Young Eun Chon, Jun Yong Park, Sung-Min Myoung, Kyu Sik Jung, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han
    American Journal of Gastroenterology.2017; 112(6): 882.     CrossRef
  • Using transient elastography to predict hepatocellular carcinoma recurrence after radiofrequency ablation
    Yu Rim Lee, Soo Young Park, Seung Up Kim, Se Young Jang, Won Young Tak, Young Oh Kweon, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang‐Hyub Han, Keun Hur
    Journal of Gastroenterology and Hepatology.2017; 32(5): 1079.     CrossRef
  • Discordance between conventional ultrasonography and ElastPQ for assessing hepatic fibrosis in chronic hepatitis B: frequency and independent factors
    Mi Sung Kim, Byung Ik Kim, Heon-Ju Kwon, Hae Won Park, Hee-Jin Park, Ki Bae Bang, Hyun Pyo Hong, Myung Ho Rho
    Journal of Medical Ultrasonics.2016; 43(2): 201.     CrossRef
  • Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus
    Ja Yoon Heo, Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Young Nyun Park, Sung Soo Ahn, Kwang-Hyub Han, Hyon-Suk Kim
    Medicine.2016; 95(14): e3328.     CrossRef
  • Hepatitis C-A clinical review
    Lan S. Wang, Lionel S. D'Souza, Ira M. Jacobson
    Journal of Medical Virology.2016; 88(11): 1844.     CrossRef
  • Autoimmune Hepatitis-related Cirrhosis
    Yan-Ni Li, Huan Ma, Lu Zhou, Jie Zhang, Li-Ping Guo, Shu-Qian Li, Yi-Qi Qian, Bang-Mao Wang
    Chinese Medical Journal.2016; 129(20): 2434.     CrossRef
  • Improvement of liver function and non‐invasive fibrosis markers in hepatitis B virus‐associated cirrhosis: 2 years of entecavir treatment
    Seung Kak Shin, Jeong Han Kim, Hyeonsu Park, Oh Sang Kwon, Hyun Jung Lee, Jong Eun Yeon, Kwan Soo Byun, Sang Jun Suh, Hyung Joon Yim, Yun Soo Kim, Ju Hyun Kim
    Journal of Gastroenterology and Hepatology.2015; 30(12): 1775.     CrossRef
  • Regression of liver cirrhosis: Orthodoxy or paradigm shift?
    Su Jong Yu
    Clinical and Molecular Hepatology.2015; 21(1): 22.     CrossRef
  • 13,104 View
  • 90 Download
  • 13 Web of Science
  • Crossref

Editorial

Viral hepatitis

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
Young Kul Jung, Ju Hyun Kim
Korean J Hepatol 2013;19(1):26-28.
Published online March 25, 2013
DOI: https://doi.org/10.3350/cmh.2013.19.1.26

Citations

Citations to this article as recorded by  Crossref logo
  • Immunological dynamics associated with rapid virological response during the early phase of type I interferon therapy in patients with chronic hepatitis C
    Jae-Won Lee, Won Kim, Eun-Kyung Kwon, Yuri Kim, Hyun Mu Shin, Dong-Hyun Kim, Chan-Ki Min, Ji-Yeob Choi, Won-Woo Lee, Myung-Sik Choi, Byeong Gwan Kim, Nam-Hyuk Cho, Eui-Cheol Shin
    PLOS ONE.2017; 12(6): e0179094.     CrossRef
  • Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
    Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong
    Gut and Liver.2017; 11(4): 543.     CrossRef
  • Phylogeny and molecular evolution of the hepatitis C virus
    Paulina Jackowiak, Karolina Kuls, Lucyna Budzko, Anna Mania, Magdalena Figlerowicz, Marek Figlerowicz
    Infection, Genetics and Evolution.2014; 21: 67.     CrossRef
  • No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
    Nae-Yun Heo, Young-Suk Lim, Woochang Lee, Minkyung Oh, Jiyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee, Dong Jin Suh
    Clinical and Molecular Hepatology.2014; 20(2): 177.     CrossRef
  • 9,522 View
  • 53 Download
  • Crossref

Original Article

Viral hepatitis

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
Seok Hoo Jeong, Young Kul Jung, Jae Won Yang, Sang Jin Park, Jong Woo Kim, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
Korean J Hepatol 2012;18(4):360-367.
Published online December 21, 2012
DOI: https://doi.org/10.3350/cmh.2012.18.4.360
Background/Aims

Sustained virologic response (SVR) for the treatment of chronic hepatitis C (CHC) may differ with ethnicity due to differences in genetic traits. This study evaluated the efficacy of peginterferon and ribavirin, and the association between IL28B genotypes and the treatment efficacy in Korean CHC patients.

Methods

This was a retrospective cohort study using data from medical records. Eighty-five CHC patients were eligible for assessment of the efficacy of antiviral therapy, and 47 patients were available for an IL28B genetic study, which was performed using the Multiplex tetra-primer PCR method for rs12979860.

Results

Overall, the early virologic response rate was 87.1%: 84.9% in HCV genotype 1 and 90.6% in genotype 2. The overall end-of-treatment virologic response rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. The overall SVR rate was 81.2%: 75.5% in genotype 1 and 90.6% in genotype 2. For rs12979860, the frequencies of polymorphisms were 89% for the CC type, 11% for the CT type, and 0% for the TT type. Their overall SVR rate was 87% (39/47): 90.5% (38/42) for the CC type and 20% (1/5) for the CT type. For genotype 1, SVR rates were 88% (21/24) for the CC type and 0% (0/4) for the CT type. Multivariate analysis revealed that the IL28B-CC type was a good predictor for SVR.

Conclusions

The SVR of the combination therapy in Koreans was higher than that observed in Western countries. This finding might be attributable to the high prevalence of IL28B-CC type among Koreans, which may be a good predictor of SVR.

Citations

Citations to this article as recorded by  Crossref logo
  • Uncovering the immune microenvironment and molecular subtypes of hepatitis B-related liver cirrhosis and developing stable a diagnostic differential model by machine learning and artificial neural networks
    Shengke Zhang, Chenglu Jiang, Lai Jiang, Haiqing Chen, Jinbang Huang, Jieying Zhang, Rui Wang, Hao Chi, Guanhu Yang, Gang Tian
    Frontiers in Molecular Biosciences.2023;[Epub]     CrossRef
  • Genetic screening to avoid adverse drug reactions from medication use and approach patients' better outcomes: A lesson learn from the report of the Queen Savang Vadhana Memorial Hospital
    Kessada Tunwongsa, Malinee Chonnawakul, Nopavut Geratikornsupuk, Karunrat Tewthanom
    Health Science Reports.2022;[Epub]     CrossRef
  • The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015
    Eun Sun Jang, Moran Ki, Hwa Young Choi, Kyung-Ah Kim, Sook-Hyang Jeong
    Hepatology International.2019; 13(5): 599.     CrossRef
  • Final Report of Unmet Needs of Interferon-Based Therapy for Chronic Hepatitis C in Korea: Basis for Moving into the Direct-Acting Antiviral Era
    Eun Sun Jang, Young Seok Kim, Kyung-Ah Kim, Youn Jae Lee, Woo Jin Chung, In Hee Kim, Byung Seok Lee, Sook-Hyang Jeong
    Gut and Liver.2017; 11(4): 543.     CrossRef
  • Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C
    Jung Hwan Yu, Jung Il Lee, Kwan Sik Lee, Ja Kyung Kim
    Virology Journal.2017;[Epub]     CrossRef
  • KASL clinical practice guidelines: management of hepatitis C

    Clinical and Molecular Hepatology.2016; 22(1): 76.     CrossRef
  • Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea
    Shinwon Lee, Sun Hee Lee, Su Jin Lee, Kye-Hyung Kim, Jeong Eun Lee, Heerim Cho, Seung Geun Lee, Joo Seop Chung, Ihm Soo Kwak
    The Korean Journal of Internal Medicine.2016; 31(4): 772.     CrossRef
  • Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin
    Chansoo Moon, Kyu Sik Jung, Do Young Kim, Oidov Baatarkhuu, Jun Yong Park, Beom Kyung Kim, Seung Up Kim, Sang Hoon Ahn, Kwang-Hyub Han
    Digestive Diseases and Sciences.2015; 60(2): 573.     CrossRef
  • IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors
    Daniele Blasquez Olmedo, Samária Ali Cader, Luís Cristóvão Porto
    Journal of Medical Virology.2015; 87(10): 1702.     CrossRef
  • No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
    Nae-Yun Heo, Young-Suk Lim, Woochang Lee, Minkyung Oh, Jiyun An, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Yung Sang Lee, Dong Jin Suh
    Clinical and Molecular Hepatology.2014; 20(2): 177.     CrossRef
  • KASL clinical practice guidelines: Management of Hepatitis C

    Clinical and Molecular Hepatology.2014; 20(2): 89.     CrossRef
  • Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
    Young Kul Jung, Ju Hyun Kim
    Clinical and Molecular Hepatology.2013; 19(1): 26.     CrossRef
  • The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean
    Ju Seung Kim, Sung-Min Ahn, Young Kul Jung, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
    Journal of Korean Medical Science.2013; 28(8): 1213.     CrossRef
  • 10,653 View
  • 37 Download
  • Crossref

Case Reports

A case of emphysematous hepatitis with spontaneous pneumoperitoneum in a patient with hilar cholangiocarcinoma
Jung Ho Kim, Eul Sik Jung, Seok Hoo Jeong, Ju Seung Kim, Yang Suh Ku, Ki Baik Hahm, Ju Hyun Kim, Yeon Suk Kim
Korean J Hepatol 2012;18(1):94-97.
Published online March 22, 2012
DOI: https://doi.org/10.3350/kjhep.2012.18.1.94

An 80-year-old woman with hilar cholangiocarcinoma was hospitalized due to sudden-onset abdominal pain. Computed tomography revealed hepatic necrosis accompanied with emphysematous change in the superior segment of the right liver (S7/S8), implying spontaneous rupture, based on the presence of perihepatic free air. Although urgent percutaneous drainage was performed, neither pus nor fluids were drained. These findings suggest emphysematous hepatitis with a hepatic mass. Despite the application of intensive care, the patient's condition deteriorated rapidly, and she died 3 days after admission to hospital. Liver gas has been reported in some clinical diseases (e.g., liver abscess) to be caused by gas-forming organisms; however, emphysematous hepatitis simulating emphysematous pyelonephritis is very rare. The case reported here was of fatal emphysematous hepatitis in a patient with hilar cholangiocarcinoma.

Citations

Citations to this article as recorded by  Crossref logo
  • Septic shock caused by emphysematous hepatitis complicated with intracranial infection
    Miao Chen, Jianbo Chen, Zhengzhi Zhuang, Xiaojun He, Yue Wang, Junwen Liang, Runpei Lin, Gengxin Cai
    IDCases.2025; 39: e02159.     CrossRef
  • A Rare Case of Emphysematous Hepatitis Managed with Surgical Debridement and Hepatic Resection
    Raneem El-Faouri, Mutaz Albrezat, Farah Jamil, Mahmoud Hmaidan
    JAPA Academy Journal.2025; 3(1): 65.     CrossRef
  • When Gas Replaces the Liver: A Rare Case of Successfully Treated Emphysematous Hepatitis
    Dirin Ukwade, Hasan S. Raza, Omar T. Ahmed, James S. Love, Maria El Gemayel, Jamie L. Berkes, Marcel Cerqueira Cesar Machado
    Case Reports in Gastrointestinal Medicine.2025;[Epub]     CrossRef
  • Emphysematous hepatitis: A case report and review of literature
    Chetoui Ayoub, Alouazen Oula, Elouafi Nabila, Oulad Amar Asmae, Alaoui Rachidi Siham
    Radiology Case Reports.2024; 19(12): 6629.     CrossRef
  • Neumoperitoneo Espontáneo Idiopático: Descripción de un caso y manejo en urgencias
    Juan Camilo Cardona Aguirre, P Vélez, J Ordoñez
    Revista Cuarzo.2024; 30(1): 38.     CrossRef
  • Medical management of feline emphysematous hepatitis—A case report
    Corinna Palko, Samuel Durkan
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Emphysematous hepatitis with successful treatments: A rare case report
    Nannan Pan, Shuo Wang, Zhenwei Miao
    Medicine.2023; 102(4): e32530.     CrossRef
  • First successful treatment of Clostridium perfringens-associated emphysematous hepatitis: a case report
    Christian Bayerl, Ann-Kathrin Berg, Stefan Angermair, Damon Kim, Bernd Hamm, Katharina Beyer, Christian Schineis
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Clostridium perfringens Liver Abscess Disguised as Biliary Disease: A Report of Two Cases and a Review of the Literature
    Jialun Peng, Qilong Zhai, Jinzheng Li, Xingyu Chen, Hongyu Wu, Tao Zhong, Gangyi Tang, Dajun Yu, Lixian He, Jinxu Li
    Infection and Drug Resistance.2023; Volume 16: 5209.     CrossRef
  • Diagnostic and Management of Emphysematous Hepatitis with Emphasis on Biopathology
    Déborah Porez, Hatem Kallel, Succes Dobian, Timotée Gerbert-Ferrendier, Mathieu Nacher, Félix Djossou, Magalie Demar, Hakim Amroun, Magaly Zappa, Kinan Drak Alsibai
    Microorganisms.2023; 11(9): 2137.     CrossRef
  • Step-up approach in emphysematous hepatitis: A case report
    Silke Francois, Maridi Aerts, Hendrik Reynaert, Ruth Van Lancker, Johan Van Laethem, Rastislav Kunda, Nouredin Messaoudi
    World Journal of Hepatology.2022; 14(2): 464.     CrossRef
  • Gas Where It Shouldn't Be! Imaging Spectrum of Emphysematous Infections in the Abdomen and Pelvis
    Pankaj Nepal, Vijayanadh Ojili, Neeraj Kaur, Sree Harsha Tirumani, Arpit Nagar
    American Journal of Roentgenology.2021; 216(3): 812.     CrossRef
  • Emphysematous hepatitis: a very rare entity with a poor prognosis
    Beatriz Estébanez-Ferrero, Orlando Fuentes-Porcel , Miguel Angel Lorenzo-Liñán, María del Mar Rico Morales
    Revista Española de Enfermedades Digestivas.2021;[Epub]     CrossRef
  • 急激な臨床経過をたどったemphysematous hepatitisの1例(Rapidly progressive septic shock due to emphysematous hepatitis: a case report)
    江﨑 有亮 (Yusuke Esaki), 古賀 靖卓 (Yasutaka Koga), 池知 大輔 (Daisuke Ikechi), 戸谷 昌樹 (Masaki Todani), 金田 浩太郎 (Kotaro Kaneda), 藤田 基 (Motoki Fujita), 鶴田 良介 (Ryosuke Tsuruta)
    Nihon Kyukyu Igakukai Zasshi: Journal of Japanese Association for Acute Medicine.2021; 32(5): 263.     CrossRef
  • Fatal emphysematous hepatitis with spontaneous pneumoperitoneum
    Asmahan Azri, Jéremie Pichon, Muriel Fartoukh, Michel Djibré
    Liver International.2020; 40(5): 1224.     CrossRef
  • Gas-Forming Liver Abscess versus Emphysematous Hepatitis: A Radiologic Diagnostic Dilemma—A Case Report and Review of the Literature
    Youssef Ghosn, Ali Abdallah, Mohammed Hussein Kamareddine, Amine Geahchan, Ahmad Baghdadi, Ziad El-Rassi, Abbas Chamseddine, Raja Ashou
    Case Reports in Hepatology.2019; 2019: 1.     CrossRef
  • Clostridium paraputrificum septicemia and liver abscess
    Yong K Kwon, Faiqa A Cheema, Bejon T Maneckshana, Caroline Rochon, Patricia A Sheiner
    World Journal of Hepatology.2018; 10(3): 388.     CrossRef
  • A rare phenomenon creating dilemma for the surgeon: Pneumoperitoneum after colonoscopy
    Ferhat Ferhatoglu, Ilker Filiz
    Sanamed.2018; 13(2): 171.     CrossRef
  • Two cases of liver abscess caused by Clostridium perfringens that potentially cured by combined modality therapy
    Tomohiro Kubo, Yutaka Kawano, Kouji Miyanishi, Kazuma Ishikawa, Akira Sakurada, Masanori Sato, Toshifumi Hoki, Fumito Tamura, Singo Tanaka, Kouichi Takada, Masayoshi Kobune, Junji Kato
    Kanzo.2017; 58(2): 105.     CrossRef
  • Spontaneous Pneumoperitoneum due to Constipation
    Ippei Yamana, Tomoaki Noritomi, Shinsuke Takeno, Tatsuya Hashimoto, Keisuke Sato, Hideki Shimaoka, Ryosuke Yamaguchi, Fumiaki Ishii, Teppei Yamada, Yuichi Yamashita
    Case Reports in Gastroenterology.2015; 9(3): 361.     CrossRef
  • Antitoxin treatment for liver abscess caused byClostridium perfringens
    Toru Hifumi, Yuichi Koido, Motohide Takahashi, Akihiko Yamamoto
    Clinical and Molecular Hepatology.2013; 19(1): 97.     CrossRef
  • 11,089 View
  • 65 Download
  • Crossref
A case of amoxicillin-induced hepatocellular liver injury with bile-duct damage
Ju Seung Kim, Young Rock Jang, Ji Won Lee, Jin Yong Kim, Young Kul Jung, Dong Hae Chung, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
Korean J Hepatol 2011;17(3):229-232.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.229

Amoxicillin, an antibiotic that is widely prescribed for various infections, is associated with a very low rate of drug-induced liver injury; hepatitis and cholestasis are rare complications. Here we present a case of a 39-year-old woman who was diagnosed with abdominal actinomycosis and received amoxicillin treatment. The patient displayed hepatocellular and bile-duct injury, in addition to elevated levels of liver enzymes. The patient was diagnosed with amoxicillin-induced cholestatic hepatitis. When amoxicillin was discontinued, the patient's symptoms improved and her liver enzyme levels reduced to near to the normal range.

Citations

Citations to this article as recorded by  Crossref logo
  • New Approach Methodologies: Physiological responses of daphnids to pharmaceutical mixtures
    Emma Rowan, Anne Leung, Katie O’Rourke, Xiaofei Yin, Lorraine Brennan, Konstantinos Grintzalis
    Journal of Hazardous Materials Letters.2025; 6: 100139.     CrossRef
  • When a Budget‐Friendly Drug Leads to a Premium Diagnosis: A Case Report of Severe Cholestasis Following Amoxicillin–Clavulanate Use
    Maureen Okafor, Joel Gabin Konlack Mekontso, Nitin Joglekar, Nikisha Pandya, John Trillo, Ned Snyder
    Case Reports in Hepatology.2025;[Epub]     CrossRef
  • Antibiotic-associated vanishing bile duct syndrome: a real-world retrospective and pharmacovigilance database analysis
    Jianglin Wang, Shengfeng Wang, Cuifang Wu, Zhenzhen Deng
    Infection.2024; 52(3): 891.     CrossRef
  • Delayed Presentation of Drug-Induced Hepatic Injury
    Shohana Ahmed, Nirmal K Onteddu, Ali Jabur, Sai Swarupa R Vulasala, Swapna Kolli
    Cureus.2020;[Epub]     CrossRef
  • Chronic amoxicillin exposure affects Labeo rohita: assessment of hematological, ionic compounds, biochemical, and enzymological activities
    Sathisaran Umamaheswari, Siva Shankar Renuka, Mathan Ramesh, Rama-Krishnan Poopal
    Heliyon.2019; 5(4): e01434.     CrossRef
  • Phenobarbital‐Induced Liver Injury With Nodal Angiomatosis
    Li‐Ting Cheng, Matthew M. Yeh, Chun‐Chi Lu
    Hepatology.2019; 70(1): 437.     CrossRef
  • Amoxicillin removal from aqueous solutions using submerged biological aerated filter
    Mohammad Ali Baghapour, Mohammad Reza Shirdarreh, Mohammad Faramarzian
    Desalination and Water Treatment.2015; 54(3): 790.     CrossRef
  • Application of urine proteomics for biomarker discovery in drug-induced liver injury
    Rachel P. L. van Swelm, Cornelis Kramers, Rosalinde Masereeuw, Frans G. M. Russel
    Critical Reviews in Toxicology.2014; 44(10): 823.     CrossRef
  • A Challenge for Diagnosing Acute Liver Injury with Concomitant/Sequential Exposure to Multiple Drugs: Can Causality Assessment Scales Be Utilized to Identify the Offending Drug?
    Roxanne Lim, Hassan Choudry, Kim Conner, Wikrom Karnsakul
    Case Reports in Pediatrics.2014; 2014: 1.     CrossRef
  • Cholestatic Hepatitis with Small Duct Injury Associated with Celecoxib
    Suresh Kumar Nayudu, Shanti Badipatla, Masooma Niazi, Bhavna Balar
    Case Reports in Medicine.2013; 2013: 1.     CrossRef
  • 16,839 View
  • 76 Download
  • Crossref
Original Articles
Genetic polymorphism at codon 10 of the transforming growth factor-β1 gene in patients with alcoholic liver cirrhosis
Jong Joon Lee, Soo Kyung Park, Oh Sang Kwon, In Sik Won, Dong Kyu Kim, Young Kul Jung, Yang Suh Ku, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim
Korean J Hepatol 2011;17(1):37-43.
Published online March 21, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.1.37
Background/Aims

Transforming growth factor beta1 (TGF-β1) is a key cytokine in the production of extracellular matrix. A genetic polymorphism at codon 10 of the TGF-β1 gene is associated with liver fibrosis. We investigated the effect of genetic polymorphisms at codon 10 on the development of alcoholic liver cirrhosis (ALC).

Methods

In total, 119 controls and 182 patients with ALC, were enrolled in the study. Clinical and laboratory data including total lifetime alcohol intake were collected at enrollment. The genotype at codon 10 was determined for each patient by single-strand conformation polymorphism.

Results

There were three types of genetic polymorphism at codon 10: homozygous proline (P/P), heterozygous proline/leucine (P/L), and homozygous leucine (L/L). Among the controls, the proportions of P/P, P/L, and L/L were 26.1%, 44.5%, and 29.4%, respectively in the ALC group, these proportions were 23.1%, 43.4%, and 33.5%, respectively. The genotype distribution did not differ between the controls and the ALC group. In the ALC group, age, total lifetime alcohol intake, and distribution of Child-Pugh class did not differ with the genotype. Of the male patients with ALC (n=164), the proportions of P/P, P/L, and L/L were 20.1%, 44.5%, and 35.4%, respectively the genotype distribution did not differ between the male controls and the male ALC patients.

Conclusions

The genotype at codon 10 in TGF-β1 does not appear to influence the development of ALC. Further study is needed to investigate other genetic factors that influence the development of ALC in patients with chronic alcohol intake.

Citations

Citations to this article as recorded by  Crossref logo
  • Alcoholic Liver Disease: Role of Cytokines
    Manuela Neuman, Yaakov Maor, Radu Nanau, Ehud Melzer, Haim Mell, Mihai Opris, Lawrence Cohen, Stephen Malnick
    Biomolecules.2015; 5(3): 2023.     CrossRef
  • Status of Primary Liver Cancer Found through Routine Health Check-up
    Changhyun Lee, Jong In Yang, Hee Jin Byun, Jung Mook Kang, Seoungho Choi, Jeong Yoon Yim
    Journal of Korean Medical Science.2013; 28(10): 1449.     CrossRef
  • Transforming growth factor-β genetic polymorphisms on development of liver cirrhosis in a meta-analysis
    Xiao-Dan Wu, Kai Zeng, Can-Sheng Gong, Jinhua Chen, Yan-Qing Chen
    Molecular Biology Reports.2013; 40(1): 535.     CrossRef
  • Cellular Mechanisms of Tissue Fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis
    Michael Zeisberg, Raghu Kalluri
    American Journal of Physiology-Cell Physiology.2013; 304(3): C216.     CrossRef
  • 9,405 View
  • 66 Download
  • Crossref
Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study
Oh Sang Kwon, Young Kul Jung, Yun Soo Kim, Sang Gyune Kim, Young Seok Kim, Jung Il Lee, Jin Woo Lee, Young Soo Kim, Byung Chul Chun, Ju Hyun Kim
Korean J Hepatol 2010;16(3):308-314.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.308
Background/Aims

Whether alcohol intake increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection remains controversial. The aim of this study was to determine the effect of alcohol intake on the development of HCC.

Methods

Between January 2006 and August 2008, 146 patients with an initial diagnosis of HCC who were hospitalized in 3 major hospitals in the Incheon area were enrolled as cases. Another 146 cirrhotic patients, who matched the cases by age and sex, were enrolled as controls. All cases and controls were HBsAg positive, and had a history of lifetime alcohol intake.

Results

The cases and controls were aged 53±8 and 53±9 years (mean±SD), respectively, with each group comprising 118 males and 28 females. The basal laboratory data, distribution of Child-Pugh class, HBeAg positivity (31.5% vs. 37.7%), HBV DNA level (5.74±2.35 vs. 5.98±2.29 log10 copies/mL), and proportion with a lifetime alcohol intake of more than 292 kg (30.8% vs. 34.9%) did not differ between cases and controls. The cumulative alcohol intake and the proportion of heavy drinkers did not differ between the two groups in male patients.

Conclusions

Alcohol intake might not increase the risk of HCC in patients with HBV infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
    Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
    Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
  • High level of serum Cripto-1 in hepatocellular carcinoma, especially with hepatitis B virus infection
    Yingyu Zhang, Hongqin Xu, Xiumei Chi, Yuxiang Fan, Ying Shi, Junqi Niu
    Medicine.2018; 97(35): e11781.     CrossRef
  • Molecular Basis of Alcohol-Related Gastric and Colon Cancer
    Hye-Kyung Na, Ja Lee
    International Journal of Molecular Sciences.2017; 18(6): 1116.     CrossRef
  • Histological improvement following administration of autologous bone marrow‐derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study
    Yoon Ok Jang, Young Ju Kim, Soon Koo Baik, Moon Young Kim, Young Woo Eom, Mee Yon Cho, Hong Jun Park, So Yeon Park, Bo Ra Kim, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Eun Hee Choi, Yong Man Kim
    Liver International.2014; 34(1): 33.     CrossRef
  • Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer
    Lei Qu, Biao Deng, Yue Zeng, Zhongwei Cao
    Cancer Cell International.2014;[Epub]     CrossRef
  • The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area
    Eun Sun Jang, Sook‐Hyang Jeong, Sang Hyub Lee, Sung Ho Hwang, So Yeon Ahn, Jaebong Lee, Young Soo Park, Jin Hyoek Hwang, Jin‐Wook Kim, Nayoung Kim, Dong Ho Lee, Hyun Young Kim
    Liver International.2013; 33(7): 1092.     CrossRef
  • Liver Cancer and Alcohol
    Priya Grewal, Vijay Anand Viswanathen
    Clinics in Liver Disease.2012; 16(4): 839.     CrossRef
  • Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma
    Xiao-Qian Chen, Juan-Ru He, Hui-Yun Wang
    Medical Oncology.2012; 29(3): 1843.     CrossRef
  • Downregulation of Polo-Like Kinase 4 in Hepatocellular Carcinoma Associates with Poor Prognosis
    Lili Liu, Chris Zhiyi Zhang, Muyan Cai, Jia Fu, George Gong Chen, Jingping Yun, Shree Ram Singh
    PLoS ONE.2012; 7(7): e41293.     CrossRef
  • 9,167 View
  • 66 Download
  • Crossref
Factors influencing the severity of acute viral hepatitis A
Joo Il Kim, Yun Soo Kim, Young Kul Jung, Oh Sang Kwon, Yeon Suk Kim, Yang Suh Ku, Duck Joo Choi, Ju Hyun Kim
Korean J Hepatol 2010;16(3):295-300.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.295
Background/Aims

Most patients with acute viral hepatitis A have a favorable course, but a few of them suffer from severe forms of hepatitis such as fulminant hepatitis. This study was carried out to identify the factors influencing the severity of acute viral hepatitis A.

Methods

We retrospectively reviewed the medical records of 713 patients with acute hepatitis A, who were divided into two groups: severe hepatitis A (N=87) and non-severe hepatitis A (N=626). Severe hepatitis was defined as fulminant hepatitis or prolongation of prothrombin time (INR≥1.5). Clinical variables were compared between the two groups.

Results

The incidence of fulminant hepatitis was 1.4% (10/713) in patients with acute hepatitis A. Thirty-three (4.6%) cases exhibited HBsAg positivity. In multivariate analyses, significant alcohol intake and the presence of HBsAg were significant predictive factors of fulminant hepatitis A, and significant alcohol intake and age were significant predictive factors of severe hepatitis A. HBeAg and HBV-DNA status did not affect the clinical course of hepatitis A in chronic hepatitis B carriers.

Conclusions

While most patients with acute hepatitis A have an uncomplicated clinical course, our data suggest that a more-severe clinical course is correlated with being older, significant alcohol intake, and chronic hepatitis-B-virus infection.

Citations

Citations to this article as recorded by  Crossref logo
  • Evolutionary principles for modifying pathogen virulence
    Tom Fieldman
    Critical Reviews in Microbiology.2024; 50(4): 385.     CrossRef
  • Association between adverse outcomes of hepatitis A and acetaminophen use: A population-based cohort study
    Gi Chan Park, Jung Wha Chung, Eun Sun Jang, Jin-Wook Kim
    Digestive and Liver Disease.2023; 55(10): 1368.     CrossRef
  • Hepatitis A virus infection
    Pierre Van Damme, Rosa M. Pintó, Zongdi Feng, Fuqiang Cui, Angela Gentile, Daniel Shouval
    Nature Reviews Disease Primers.2023;[Epub]     CrossRef
  • Gender Impacts on the Disease Severity of Overt Acute Hepatitis A: Different from Overt Acute Hepatitis B
    Ming-Ling Chang, Yun-Fan Liaw
    Digestive Diseases and Sciences.2019; 64(2): 570.     CrossRef
  • Recovery from hepatitis A after Korean medicine-based treatment: a case report
    Chan-Ran Park, Gayoung Lee, Chang-Gue Son, Jung-Hyo Cho, Nam-Hun Lee
    Integrative Medicine Research.2019; 8(4): 257.     CrossRef
  • Predictors of Acute Liver Failure in Patients With Acute Hepatitis A: An Analysis of the 2016–2018 San Diego County Hepatitis A Outbreak
    Aiyang A Jiang, Holly S Greenwald, Lamiya Sheikh, Darcy A Wooten, Atul Malhotra, Robert T Schooley, Daniel A Sweeney
    Open Forum Infectious Diseases.2019;[Epub]     CrossRef
  • Vaccination of Hepatitis A; To Do or Not to Do?
    Seyed Farshad Allameh, Morteza Daraie, Reza Taslimi, Nader Roshan, Najmeh Aletaha, Mohsen Nasiri Toosi
    Middle East Journal of Digestive Diseases.2017; 9(4): 246.     CrossRef
  • Conjugated Bilirubin Differentially Regulates CD4+ T Effector Cells and T Regulatory Cell Function through Outside-In and Inside-Out Mechanisms: The Effects of HAV Cell Surface Receptor and Intracellular Signaling
    Karla F. Corral-Jara, Jorge L. Trujillo-Ochoa, Mauricio Realpe, Arturo Panduro, Juan F. Gómez-Leyva, Yvonne Rosenstein, Alexis Jose-Abrego, Sonia Roman, Nora A. Fierro
    Mediators of Inflammation.2016; 2016: 1.     CrossRef
  • Seroprevalence of Hepatitis A Virus Antibodies among the Patients with Chronic Hepatitis B in Turkey
    Necla Tulek, Metin Ozsoy, Cigdem Moroglu, Meliha Cagla Sonmezer, Fatih Temocin, Gunay Tuncer Ertem, Fatma Sebnem Erdinc
    Euroasian Journal of Hepato-Gastroenterology.2015; 5(2): 95.     CrossRef
  • Clinical Features and Risk Factors for Severe Complications among Patients with Acute Hepatitis A Virus Infection in The Jeonbuk Province of Korea
    Sun Ho Yoo, In Hee Kim, Ji Won Jang, Chung Hwan Choi, Jin Chang Moon, Jin Kyoung Park, Sang Youn Lee, Seong Hun Kim, Sang Wook Kim, Seung Ok Lee, Soo Teik Lee, Dae Ghon Kim, Eun Young Cho, Gum Mo Jung
    The Korean Journal of Gastroenterology.2014; 63(1): 25.     CrossRef
  • Does chronic hepatitis B infection affect the clinical course of acute hepatitis A?
    Su Rin Shin, In Ho Moh, Sung Won Jung, Jin Bae Kim, Sang Hoon Park, Hyoung Su Kim, Myung Kuk Jang, Myung Seok Lee
    Journal of Medical Virology.2013; 85(1): 43.     CrossRef
  • A Case of Severe Acute Hepatitis A Complicated with Pure Red Cell Aplasia
    Pyoung Suk Lim, In Hee Kim, Seong Hun Kim, Seung Ok Lee, Sang Wook Kim
    The Korean Journal of Gastroenterology.2012; 60(3): 177.     CrossRef
  • Epidemiological changes in hepatitis A in Korea: increasing age and its effect on clinical outcomes
    J. J. SHIM, S. O. CHIN, C. K. LEE, J. Y. JANG, B. H. KIM
    Epidemiology and Infection.2012; 140(12): 2182.     CrossRef
  • Is Evaluation of Hepatitis A Immunity Required or Not?
    Gholam Ali Ghorbani
    Hepatitis Monthly.2011; 11(12): 955.     CrossRef
  • A nationwide seroprevalence of total antibody to hepatitis A virus from 2005 to 2009: age and area-adjusted prevalence rates
    Donghun Lee, Moran Ki, Anna Lee, Kyoung-Ryul Lee, Hee Bong Park, Chang Sub Kim, Bo Young Yoon, Jong Hyun Kim, Young Sok Lee, Sook-Hyang Jeong
    The Korean Journal of Hepatology.2011; 17(1): 44.     CrossRef
  • Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea
    Sang Ho Lee, Hyoung Su Kim, Kwon Oh Park, Jong Won Park, Seung Yeon Chun, Seung Jin Lim, Hyun Jung Cho, Sung Jun Kim, Hye Won Park, Han Kook Moon, Woon Geon Shin, Kyung Ho Kim, Myoung Kuk Jang, Jin Heon Lee, Hak Yang Kim
    The Korean Journal of Hepatology.2010; 16(4): 362.     CrossRef
  • 10,203 View
  • 88 Download
  • Crossref